Your browser is no longer supported. Please, upgrade your browser.
Settings
GSK GlaxoSmithKline plc daily Stock Chart
GSK [NYSE]
GlaxoSmithKline plc
Index- P/E92.18 EPS (ttm)0.46 Insider Own0.20% Shs Outstand2.43B Perf Week0.12%
Market Cap102.64B Forward P/E15.13 EPS next Y2.80 Insider Trans0.00% Shs Float2.43B Perf Month3.12%
Income1.13B PEG6.73 EPS next Q- Inst Own9.00% Short Float0.26% Perf Quarter12.02%
Sales34.56B P/S2.97 EPS this Y-89.20% Inst Trans1.44% Short Ratio1.89 Perf Half Y0.46%
Book/sh0.57 P/B74.23 EPS next Y0.97% ROA1.60% Target Price47.00 Perf Year12.97%
Cash/sh2.55 P/C16.61 EPS next 5Y13.70% ROE78.60% 52W Range36.69 - 43.93 Perf YTD11.41%
Dividend2.00 P/FCF- EPS past 5Y-28.90% ROI8.60% 52W High-3.79% Beta0.97
Dividend %4.73% Quick Ratio0.60 Sales past 5Y0.40% Gross Margin68.10% 52W Low15.20% ATR0.36
Employees99827 Current Ratio0.90 Sales Q/Q20.70% Oper. Margin9.30% RSI (14)71.75 Volatility0.65% 0.78%
OptionableYes Debt/Eq16.72 EPS Q/Q171.00% Profit Margin3.30% Rel Volume0.58 Prev Close42.31
ShortableYes LT Debt/Eq13.04 EarningsJan 25 Payout426.60% Avg Volume3.32M Price42.26
Recom2.00 SMA201.10% SMA505.11% SMA2004.50% Volume142,940 Change-0.12%
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Mar-24-17 07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
Mar-23-17 05:06PM  Why Google Needs to Forcefully Address Its Video Ad Problem
01:04PM  GLAXOSMITHKLINE PLC Financials
10:09AM  J&J, GlaxoSmithKline Latest to Pull Ads From Google Amid Concerns About Offensive Content at TheStreet
07:21AM  Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Reuters
Mar-22-17 08:01PM  GSK and Regeneron to mine gene data from 500,000 Britons
10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017
09:06AM  Xifaxan Expected to Witness Robust Growth in 2017
Mar-21-17 02:58PM  Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
02:13PM  Still Bullish on GlaxoSmithKline
12:13PM  7 Pharma Plays With Emerging Market Potential at Barrons.com
09:18AM  6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar-20-17 06:22PM  Novartis (NVS) Announces Positive Data on Heart Failure Drug
10:32AM  AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
Mar-17-17 09:45AM  AstraZeneca Inks $230 Million COPD Drugs Deal at Investopedia
07:38AM  A Look at Opdivos Performance in 2016
Mar-16-17 12:00PM  Glaxo Seeks Label Expansion for Fluarix Vaccine at Investopedia
08:59AM  Glaxo Files for Label Expansion of Influenza Vaccine in US
Mar-15-17 12:07PM  GSK: New Female CEO Gets 25% Less Than Predecessor at Investopedia
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
11:13AM  GSK announces US regulatory submission seeking expanded indication for Fluarix® Quadrivalent (Influenza Vaccine) for infants 6 months and older PR Newswire
09:30AM  The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines
05:45AM  Once paid by Vertex, Trump's FDA pick would be tasked with regulating it at bizjournals.com
Mar-14-17 03:23PM  Top Research Reports for Intel, Schwab & Glaxo
11:38AM  Couple sue pharma giant for work that led to prison in China
11:12AM  How a Major Drugmaker Plans to Cure Disease... Without Drugs at Motley Fool
10:29AM  Glaxo to Pay First Woman CEO Less, Cites Lack of Experience
09:28AM  Its time to vaccinate your investments against a deadly bird flu at MarketWatch
Mar-10-17 10:30AM  Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
09:21AM  Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
Mar-09-17 02:35PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
11:02AM  Gilead: "Stuck Between A Rock And A Hard Place?" at Barrons.com
08:49AM  Coverage initiated on GlaxoSmithKline by Kepler and Liberum
Mar-08-17 10:35AM  Trump rally on pause: Stocks, Dow Jones sluggish despite strong ADP jobs report: Snap, Goldman, BofA, Urban Outfitters on the move at bizjournals.com
Mar-07-17 04:21PM  Novartis (NVS) Reports Positive Data on Biosimilar Humira
04:08PM  GlaxoSmithKline's Nucala Positive in Label Expansion Study
Mar-06-17 11:43AM  Why GlaxoSmithKline plc Edged Higher in February at Motley Fool
10:20AM  GSK's MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype PR Newswire
08:23AM  3 Tempting High-Yield Dividend Stocks You Should Avoid at Motley Fool
Mar-03-17 05:08AM  GSK's Board Faces Pressure Over Incoming CEO's Pay
Mar-02-17 04:46PM  Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View
12:12PM  These 3 Big Pharma Stocks Are Exceptionally Cheap at Motley Fool
09:30AM  Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Mar-01-17 03:19PM  M&As, Pipeline Catalysts to Drive Pharma Sector
Feb-28-17 12:17PM  Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
10:37AM  Januvia, Vaccines May Drive Mercks Revenue Growth in 2017
09:30AM  Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly
Feb-27-17 11:23AM  Why I'm Optimistic About GlaxoSmithKline
10:36AM  Eli Lilly and Co.s New Products Portfolio
Feb-25-17 09:34AM  Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc at Motley Fool
Feb-24-17 07:27AM  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
Feb-23-17 10:12AM  Top Ranked Growth Stocks to Buy for February 23rd
09:58AM  Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
05:00AM  Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma Business Wire
Feb-22-17 05:08PM  Pfizer's Leukemia Candidate Gets Priority Review in U.S.
04:31PM  Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs
12:42PM  Biotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments at Barrons.com
Feb-21-17 01:38PM  Korn Ferry Futurestep Partners with GlaxoSmithKline to Support Talent Acquisition Business Wire
Feb-19-17 10:14PM  If You Want Yield, Look to the UK
Feb-18-17 12:09PM  2 High-Yield Dividend Stocks That Are Ridiculously Cheap at Motley Fool
Feb-17-17 04:46PM  Inside Sanofis Revenues in 4Q16
02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb-16-17 04:25PM  Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
04:19PM  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
09:05AM  GlaxoSmithKlines Valuation Compared to Its Peers
07:35AM  GlaxoSmithKlines Consumer Healthcare Reports Growth in 4Q16
03:29AM  British Blue Chips Snub Investor Calls to Show CEO Pay Ratio at Bloomberg
Feb-15-17 10:36AM  GlaxoSmithKlines Vaccines Business Reported Growth in 4Q16
10:08AM  AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
07:37AM  GlaxoSmithKlines HIV Business in 4Q16
Feb-14-17 04:39PM  ETFs with exposure to GlaxoSmithKline Plc : February 14, 2017
04:19PM  Gilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet
03:19PM  GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming at Motley Fool
03:05PM  Performance of GlaxoSmithKlines Pharmaceuticals Segment in 4Q16
01:35PM  4Q16 Performance of GlaxoSmithKlines Business Segments
12:10PM  GlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake at Insider Monkey
11:46AM  GlaxoSmithKlines Revenue Trend for 4Q16
11:17AM  Gilead Sciences: Not Out of the Woods Yet? at Barrons.com
09:32AM  Lilly's Olumiant Gets Marketing Authorization in Europe
03:47AM  Gilead challenges GSK with strong HIV drug data
Feb-13-17 08:40PM  Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference
07:55PM  PRESS DIGEST- Financial Times - Feb 14
06:45PM  [$$] GSK claims new HIV combination therapy will be 'less harmful' at Financial Times
04:25PM  Can Gilead Swivel To HIV Amid Floundering Hep C Sales, GSK Rivalry?
10:41AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017
Feb-10-17 11:09AM  Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
09:06AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-09-17 12:58PM  Gilead to Battle GlaxoSmithKline for HIV Cure at Investopedia
10:36AM  Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
Feb-08-17 08:30PM  PRESS DIGEST- British Business - Feb 9
04:21PM  Allergan Leads Drug Stocks On View-Crushing Q4, 2016, 2017 Guidance
01:30PM  [$$] GSK beats forecasts but braces for asthma drug challenge at Financial Times
01:28PM  Gilead: Where's the Bottom? at Barrons.com
12:22PM  FTSE 100 ekes out a slight gain ahead of key Brexit vote at MarketWatch
12:22PM  Vaccine Sales Help GSK Results, Shares Up at Investopedia
11:57AM  GSK warns profits to be hit by generic drugs competition
11:54AM  [$$] GlaxoSmithKline Warns of Hit From Advair Copycat at The Wall Street Journal
11:50AM  GlaxoSmithKline and Gilead to face off at HIV meeting next week
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV, as well as oncology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM